Glenmark gets tentative USFDA nod for prostate cancer treatment drug

PTI New Delhi | Updated on January 23, 2019 Published on January 23, 2019

Glenmark Pharmaceuticals has received a tentative nod from the US health regulator for Abiraterone Acetate tablets, used in the treatment of prostate cancer.

Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food and Drug Administration for Abiraterone Acetate tablets USP in the strength of 250 mg, the company said in a BSE filing on Wednesday.

The approved product is a generic version of Janssen Biotech Inc’s Zytiga tablets.

Quoting IQVIA sales data for the 12-month period ended November 2018, Glenmark Pharmaceuticals said, the Zytiga tablets 250 mg market achieved annual sales of approximately $1.3 billion.

The company’s current portfolio consists of 148 products authorised for distribution in the US market and 54 abbreviated new drug applications (ANDAs) pending approval with the USFDA.

Shares of Glenmark Pharmaceuticals were trading 1.17 per cent lower at Rs 648.45 apiece on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 23, 2019
This article is closed for comments.
Please Email the Editor